Where does Roche Glycart AG rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Roche Glycart AG ranks #6,183 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Roche Glycart AG hold?

Roche Glycart AG holds 55 US utility patents granted between 2015 and 2025, spanning 11 technology areas.

What is Roche Glycart AG's Innovation Score?

Roche Glycart AG has an Innovation Score of 39.6 out of 100 (top 38% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Roche Glycart AG focus on?

Roche Glycart AG's top technology area is C07K (Peptides) with 55 patents, ranking #153 of 3,615 assignees active in that subclass. Grants appear in 11 CPC subclasses total.

Is Roche Glycart AG's patent grant rate increasing or decreasing?

Roche Glycart AG's recent grant velocity is -68% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Roche Glycart AG's patents?

Roche Glycart AG's patents average 19.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Roche Glycart AG patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Roche Glycart AG

USPTO PatentsView assignee record - 55 granted patents across 11 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Roche ranks #6,183 of 49,997 tracked US assignees by granted-patent volume, with 55 patents across 11 technology areas.

#6,183
of 49,997 US assignees by volume: Top 38%
by Innovation Score (39.6/100): 19.6
avg claims per patent: -68%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R6183 · Foreign Corporation #6,183 · 55 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 55 grants
UPPER-Q #6,183/49,997
PHOTO-FINISH Plant 21
CPC-FOCUS C07K · 11 areas
INNOV-THIN 39.6/100
CLAIMS-RICH 19.6 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -68% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Plant 21 LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Roche’s 39.6 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 13.9 pts (35%) Velocity 2.2 pts (6%) Breadth 11.7 pts (30%) Claim depth 11.7 pts (30%)

Qualcomm Incorporated · highest

85
Locix · near

40
Roche Glycart · this assignee

40
Sirrus · near

40
Tokyo Metropolitan… · near

40
Valmet Aktiebolag · near

40
3D Lighting… · lowest

7

What this shows Roche's Innovation Score is 39.6/100 (top 38% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Roche?

Each dot is one of Roche’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Roche’s own 19.6 claims/patent is ABOVE the 12.7 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Roche vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Roche's grants concentrate

Roche Glycart AG is a focused PatentsView assignee: 11 CPC subclasses with 100% of grants classified under C07K (Peptides). Peak complete grant year is 2016 (12 grants) versus a trough of 1 in 2023. By volume, Roche sits between Prysm, Inc. and Sigmastar Technology Ltd..

Roche's three-year grant acceleration

Roche Glycart AG shows 5 grants in 2022–2024 against only 15 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Prysm

55
Plant 21

55
Rotam Agrochem In…

55
Roche Diagnostics…

55
Rockwell Automati…

55
SDI

55
Shenzhen Valuelin…

55
Sigmastar Technol…

55
Roche Glycart ◀

55

What this shows Roche holds 55 patents at rank #6,183, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Roche

By rank, the assignees closest to #6,183 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Roche's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Roche, neither rank-band nor same-CPC leaders (those blocks stay above). In C07K (Peptides), Roche ranks #153 of 3,615 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (40 here).

Sirrus, Inc. 40 Valmet Aktiebolag 40 Tokyo Metropolitan Institute OF Medical Science 40 Locix, Inc. 40

Similar claim depth

Nearest assignees by average claims per patent (19.6 here).

Capstan Ag Systems, Inc. 19.6 avg Ferroelectric Memory GmbH 19.6 avg Inmar Clearing, Inc. 19.6 avg Entropic Communications, LLC 19.6 avg

Roche's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

40 Top 38% higher than 62% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Roche Glycart AG patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	8	14.5%
2016	12	21.8%
2017	6	10.9%
2018	8	14.5%
2019	7	12.7%
2020	5	9.1%
2021	3	5.5%
2022	4	7.3%
2023	1	1.8%
2025partial year	1	1.8%

Which technologies does Roche Glycart AG patent most?

C07K - Peptides 55

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 51

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 43

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 8

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 5

Y10S - Technical Subjects Covered BY Former Uspc Cross-reference ART Collections [XRACs] AND Digests 4

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 3

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 3

C12Y - Enzymes 2

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 1

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 1

Top 11 of 11 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Roche Glycart AG's patent record in context - here's where to go next.

Roche Glycart AG's lead technology class is C07K (Peptides), 100% of its portfolio - see every assignee active in that class. Explore C07K
Ranked #6,183 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Roche Glycart AG against Prysm, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 39.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.